logo
Gastrointestinal cancers rising dramatically in people under 50

Gastrointestinal cancers rising dramatically in people under 50

Yahooa day ago
Gastrointestinal cancers, which include colorectal, stomach and pancreatic cancer, are rising dramatically in younger adults, though doctors aren't fully sure why. Even some of the possible causes require more research, they say.
According to a review published Thursday in JAMA, gastrointestinal cancers have become the fastest-growing type of cancers diagnosed in adults younger than 50 in the U.S..
The review, one of the most comprehensive looks at gastrointestinal cancer trends, summarized the findings of major international and U.S. cancer databases, plus 115 papers on gastrointestinal cancers published from January 2014 to March 2025.
The authors underscore the need for people to follow the screening guidelines for colorectal cancer, which suggest that people with an average risk start screening — usually a colonoscopy or stool test — at age 45. Since doctors don't routinely screen for pancreatic, stomach and esophageal cancers in the U.S., the authors also call for new ways to screen more people for these cancers.
'This really points to the importance of trying to improve screening and early detection,' said Dr. Kimmie Ng, the review's co-author and director of the Young-Onset Colorectal Cancer Center at Dana-Farber Cancer Institute.
According to the review, colorectal cancer is by far the most common early-onset gastrointestinal cancer, with nearly 185,000 cases reported worldwide in 2022 and nearly 21,000 cases reported that same year in the U.S. Diagnoses in the U.S. have risen 2% annually in people younger than 50 since 2011, according to the American Cancer Society.
'It never used to happen in this age group, and now a very significant rise in 20, 30 and 40-year-olds are getting colon cancer,' said Dr. John Marshall, chief medical consultant at the nonprofit Colorectal Cancer Alliance, who was not involved in the research. In one of the most high-profile examples, actor Chadwick Boseman was diagnosed with colon cancer in 2016 and passed away of the disease four years later at age 43.
Early-onset cases of pancreatic, stomach and esophageal cancers are also rising, according to the new study. Previous research has shown a disproportionate share of those gastrointestinal cancer diagnoses were among Black and Hispanic people. Pancreatic cancer is among the deadliest forms of cancer, with just 13% of patients surviving five years after their diagnosis.
Because colorectal cancer is the most common, doctors said they have a better grasp of what might be contributing to these early-onset cases compared to others.
'If we can understand what's going on in colorectal [cancer], I think it would really provide a lot of guidance to help us understand the other GI tract cancers,' said Dr. Scott Kopetz, a professor of gastrointestinal medical oncology at the University of Texas MD Anderson Cancer Center.
Kopetz said there are likely multiple factors driving the increase in early-onset cases.
'The leading theory is that there is no single leading theory,' he said.
Ng's new review in JAMA suggests that most gastrointestinal cancers in people under 50 are associated with lifestyle factors such as obesity, lack of exercise, poor diet, cigarette smoking or alcohol consumption. One study included in the review found that women who consumed more sugar-sweetened beverages during adolescence had a higher risk of developing early onset colorectal cancer.
'It's really what people were doing or exposed to when they were infants, children, adolescents that is probably contributing to their risk of developing cancer as a young adult,' Ng said.
Health and Human Services Secretary Robert F. Kennedy Jr. has been vocal about the association between sugary beverages and health issues, including cancer. On Wednesday, President Donald Trump said Coca-Cola will start being made with cane sugar rather than corn syrup in the U.S., but the company did not commit to the change when asked about it by NBC News.
Marshall said he suspects the rise in early-onset colorectal cancer could have something to do with changes in people's gut microbiomes — the bacteria that live in our gastrointestinal tracts. Diet, antibiotic use, microplastics and exposure to environmental chemicals likely all influence a person's gut bacteria, but scientists still don't have a clear understanding of what a healthy microbiome looks like nor how it affects our health. That is a booming area of research.
Ng's review also found that 15% to 30% of people with early-onset gastrointestinal cancer carry hereditary genetic mutations that may have predisposed them to getting cancer at a young age. Because of that, she said, 'we do recommend that all young patients diagnosed under the age of 50 undergo testing for hereditary conditions.'
Overall survival rates for gastrointestinal cancers have gotten better over time, due to improvements in treatment and screening. But Ng's review found that younger patients often have worse outcomes, despite typically receiving more treatments, including more surgery, radiation and aggressive combinations of chemotherapy, she said.
One reason could be that primary care doctors may overlook symptoms such as abdominal pain, constipation, heartburn or reflux in younger patients, thereby delaying their diagnoses.
'My personal feeling is that it's because we're finding them at a more advanced stage, because people don't really think of colon or other GI cancers when they see a young person with these non-specific complaints,' said Dr. Howard Hochster, director of gastrointestinal oncology at Rutgers Cancer Institute and RWJBarnabas Health in New Jersey.
But Ng said that even after controlling for the stage at which patients are diagnosed, young people still seem to have worse survival rates.
'This makes us wonder as researchers whether that means that the cancers that develop in younger people may be biologically different and more aggressive, or maybe less responsive to treatment,' she said.
This article was originally published on NBCNews.com
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Michael Madsen cremated, more details about actor's death emerge
Michael Madsen cremated, more details about actor's death emerge

Yahoo

time18 minutes ago

  • Yahoo

Michael Madsen cremated, more details about actor's death emerge

Actor Michael Madsen was cremated this week following his death earlier his month, about which more details are now emerging. A number of conditions, including cardiomyopathy — which makes it more difficult for the heart to pump blood throughout the body — along with coronary artery disease and chronic alcoholism all contributed to the cardiac arrest that ultimately killed the 67-year-old 'Kill Bill' star, according to a death certificate issued by Los Angeles County Medical Examiner and obtained by TMZ on Thursday. Thromboembolic disease, when vessels or arteries are blocked by blood clots, was also identified as a significant contributing factor. The death certificate shows that Madsen, who'd reportedly gotten sober in recent months, died less than two months after undergoing coronary angiography, which uses X-rays to look at the heart's blood vessels, per Mayo Clinic. Madsen's manager Ron Smith previously confirmed to NBCLA that Madsen died at his Malibu, California, home on July 3 from cardiac arrest. Days later, Madsen's cardiologist told the outlet that heart disease and alcoholism would be listed as contributing factors to his heart failure. Sister and fellow actor, Oscar nominee Virginia Madsen, remembered her big brother as 'half legend, half lullaby' — 'etched in contradiction, tempered by love that left its mark.' Madsen is survived by four children, including his son Christian, who is also an actor. He was predeceased by one of his sons, Hudson, who died by suicide in 2022.

Rare 'flesh-eating' bacteria claims 4 lives in Florida: What to know
Rare 'flesh-eating' bacteria claims 4 lives in Florida: What to know

Yahoo

time18 minutes ago

  • Yahoo

Rare 'flesh-eating' bacteria claims 4 lives in Florida: What to know

Florida health officials reported that four people died and over a half dozen others were made sick this year by a rare "flesh-eating" bacteria. Vibrio vulnificus, which is found in saltwater, brackish water and inside contaminated raw or undercooked seafood, led to four deaths in four counties across the state and made at least seven people ill, the state's Department of Health announced on July 11. Infection from the bacteria is rare, with an average of 150 to 200 cases reported each year to the Center for Disease Control and Prevention (CDC). Cases are most often reported in the Gulf Coast states, though research has shown it migrating north as climate change fuels warmer oceans. Most healthy people exposed to the bacteria experience only mild symptoms. For some, however, the bacteria can be deadly – especially if it enters the bloodstream or kills flesh around an open wound. About one in five people die from the infection, according to the CDC, sometimes within one to two days of becoming ill. Others may require surgery or even amputation after their exposure. Here's what to know about Vibrio vulnificus: Where is Vibrio vulnificus located? Vibrio are bacteria that naturally live in coastal waters year-round. Vibrio vulnificus requires saltwater to live and spread, though it can thrive in brackish water, where a stream or river meets seawater. Most infections occur when people swallow contaminated water or get it in an open wound. Another source of infection is contaminated raw or undercooked seafood, especially shellfish such as oysters. In Florida, which leads the nation in Vibrio vulnificus infections, spikes in cases and deaths coincide with major hurricanes, when seawater is carried on shore, triggering flooding and dumping seawater into freshwater sources. Between 2016 to 2024, an average of 48 Vibrio vulnificus cases and about 11 deaths were reported annually in Florida. In 2022, when Hurricane Ian battered communities along the southwest coast, there were 74 reported cases and 17 deaths. Last year, the state recorded 82 cases and 19 deaths – a surge health officials tied to a pair of damaging hurricanes, Helene and Milton. Why is it called a 'flesh-eating bacteria'? Vibrio vulnificus kills, but does not eat tissue. The bacteria cannot penetrate unharmed skin, but can enter through an existing break. If the bacteria enters the body through a cut, scrape or wound, it can cause necrotizing fasciitis, and the flesh around the infection site could die. Those infected through wounds may require major surgery or limb amputations, according to the CDC. What are the symptoms of Vibrio vulnificus? Common symptoms of Vibrio vulnificus infection include diarrhea, stomach cramps, nausea, vomiting and fever, according to the CDC. When open wounds are exposed to contaminated salt or brackish water, Vibrio vulnificus can cause discoloration, swelling, skin breakdown and ulcers. The bacteria can also invade the bloodstream and threaten severe and life-threatening illnesses such as septic shock, especially for those with pre-existing conditions. "Vibrio vulnificus bloodstream infections are fatal about 50 percent of the time," according to the Florida Department of Health. How to avoid Vibrio vulnificus Below are some tips to avoid Vibrio vulnificus, according to the Florida Department of Health and the CDC. Stay out of saltwater and brackish water if you have an open wound or cut. If you get a cut while you are in the water, leave the water immediately. If your open wounds and cuts could come in contact with salt water, brackish water or raw or undercooked seafood, cover them with a waterproof bandage. Cook shellfish (oysters, clams, mussels) thoroughly. Avoid cross-contamination of cooked seafood and other foods with raw seafood and juices from raw seafood. Always wash your hands with soap and water after handling raw shellfish. Seek medical attention right away for infected wounds. Contributing: Natalie Neysa Alund, Thao Nguyen, Gabe Hauari and Mike Snider, USA TODAY; C.A. Bridges, USA TODAY Network - Florida This article originally appeared on USA TODAY: Rare 'flesh-eating' bacteria kills 4 people in Florida: What to know Solve the daily Crossword

Rapid Review: Endometrial Cancer
Rapid Review: Endometrial Cancer

Medscape

time20 minutes ago

  • Medscape

Rapid Review: Endometrial Cancer

In endometrial cancer, the majority of cases are diagnosed at an early stage, largely due to the hallmark symptom of postmenopausal bleeding. Despite relatively favorable survival rates when caught early — with a 5-year relative survival rate of approximately 95% for localized disease — disparities remain in detection, treatment access, and mortality. ctDNA testing has shown strong value as a noninvasive and highly sensitive method for detecting recurrence in endometrial cancer. ctDNA detects tumor-specific mutations in the bloodstream and is being actively evaluated to track cancer progression, detect early-stage cancers, and monitor therapeutic responses. ctDNA's role for detecting hormone receptor status and tumor histology has not been established for endometrial cancer, and it appears to not be correlated with myometrial invasion depth. Learn more about the presentation of endometrial cancer. In the past year, evidence has emerged which demonstrates that GLP-1 receptor agonists — medications originally approved for diabetes and obesity — reduce the risk for obesity-related cancers. A major research effort found that these drugs decreased cancer incidence, and further research found GLP-1 receptor agonists to be comparable to bariatric surgery for obesity-related cancer prevention. GLP-1 therapies now offer a less-invasive alternative to bariatric surgery. Research is ongoing to evaluate the use of GLP-1 medications as a potential therapeutic strategy for endometrial cancer. The other classes have not been shown to reduce risk or are not used in endometrial cancer management. Learn more about the differential diagnosis for endometrial cancer. Recent advances in molecular and genomic profiling have significantly refined the precision with which therapies can be selected for patients with endometrial cancer. These tools enable clinicians to pinpoint genetic and molecular characteristics that dictate tumor behavior and response to treatment, improving personalized treatment strategies and overall survival outcomes. Rather than uniformly applying treatments, clinicians have the ability to tailor therapies based on individual molecular profiles. Adjuvant therapy may still be warranted depending on the risk associated with the molecular/genomic subtypes identified, and best practice histopathology evaluation is still needed even when advanced profiling is done. Further research continues to expand the depth and breadth of genomic profiling, making it a crucial element of modern oncology practice. Learn more about the workup for endometrial cancer. The TCGA molecular classification divides endometrial cancers into four biologically distinct subtypes: POLE-ultramutated, MSI-H, copy number-low (endometrioid), and copy number-high (serous-like). These molecular profiles provide prognostic insights and increasingly guide therapeutic strategies beyond traditional histology and staging. For example, POLE-mutated tumors, despite high mutation burdens, have excellent outcomes and may not require aggressive adjuvant therapy. In contrast, copy number-high tumors are associated with poor prognosis and may benefit from more intensive treatment and HER2-targeted therapies. This classification is part of a shift toward personalized medicine in gynecologic oncology. Learn more about guidelines for endometrial cancer. Compared to traditional open surgery, MIS dramatically shortens hospital stays, decreases blood loss, and has fewer overall complications, although it does lengthen operation time. Furthermore, minimally invasive approaches maintain oncologic outcomes comparable to those of traditional open surgery, providing reassurance regarding their safety and efficacy. Because endometrial cancer patients often have obesity, MIS has the potential to reduce the risk for postoperative wound complications. It also is likely to decrease other postoperative morbidities by supporting faster recovery and earlier resumption of normal daily activities. Additionally, lymph node assessment may still be needed after MIS. Learn more about risk assessment in patients with endometrial cancer.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store